keyword
MENU ▼
Read by QxMD icon Read
search

Cancer ovarian

keyword
https://www.readbyqxmd.com/read/28448857/fifth-ovarian-cancer-consensus-conference-of-the-gynecologic-cancer-intergroup-recommendations-on-incorporating-patient-reported-outcomes-in-clinical-trials-in-epithelial-ovarian-cancer
#1
Florence Joly, Felix Hilpert, Aikou Okamoto, Gavin Stuart, Kasunori Ochiai, Michael Friedlander
Despite the support for including patient-reported outcomes (PROs) and health-related quality of life in clinical trials, there have been deficiencies in how these have been assessed and reported in epithelial ovarian cancer (EOC) clinical trials. To redress this, the 5th Ovarian Cancer Consensus Conference, included a plenary session entitled 'How to include PROs in clinical trials'. The perspective is a summary of the recommendations made by the Gynecologic Cancer InterGroup unanimously agreed on the importance of PROs and PRO end-points in EOC clinical trials...
April 24, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28448787/relationship-between-her2-and-jak-stat-socs3-signaling-pathway-and-clinicopathological-features-and-prognosis-of-ovarian-cancer
#2
An-Quan Shang, Jian Wu, Feng Bi, Yu-Jie Zhang, Lei-Rong Xu, Ling-Ling Li, Fei-Fei Chen, Wei-Wei Wang, Jian-Jun Zhu, You-Yi Liu
OBJECTIVE: The study aims to explore the relationship between expressions of HER2 and JAK/STAT3-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer (OC). METHODS: A total of 136 OC patients were collected. Immunohistochemistry was applied to measure the expressions of STAT3, p-STAT3, SOCS3, HER2 and p-HER2 in the tumor tissues and adjacent normal tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of HER2, SOCS3 and STAT3 and western blotting was applied for protein expressions of HER2, p-HER2, SOCS3, STAT3 and p-STAT3 in the tumor tissues and adjacent normal tissues...
April 27, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28448592/blood-type-abo-genetic-variants-and-ovarian-cancer-survival
#3
Gabriella D Cozzi, Rebecca T Levinson, Hilary Toole, Malcolm-Robert Snyder, Angie Deng, Marta A Crispens, Dineo Khabele, Alicia Beeghly-Fadiel
OBJECTIVE: Blood type A and the A1 allele have been associated with increased ovarian cancer risk. With only two small studies published to date, evidence for an association between ABO blood type and ovarian cancer survival is limited. METHODS: We conducted a retrospective cohort study of Tumor Registry confirmed ovarian cancer cases from the Vanderbilt University Medical Center with blood type from linked laboratory reports and ABO variants from linked Illumina Exome BeadChip data...
2017: PloS One
https://www.readbyqxmd.com/read/28448435/a-resident-s-perspective-of-ovarian-cancer
#4
Christopher G Smith
Identifying, understanding, and curing disease is a lifelong endeavor for any medical practitioner. Equally as important is to be cognizant of the impact a disease has on the individual suffering from it, as well as on their family. Ovarian cancer is the leading cause of death from gynecologic malignancies. Symptoms are vague, and the disease is generally at an advanced stage at diagnosis. Efforts have been made to develop methods to identify ovarian cancer at earlier stages, thus improving overall mortality...
April 27, 2017: Diagnostics
https://www.readbyqxmd.com/read/28447911/is-there-a-role-for-ovarian-cancer-screening-in-high-risk-women
#5
Andrew Berchuck, Laura J Havrilesky, Noah D Kauff
No abstract text is available yet for this article.
May 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28447160/cancer-of-the-ovary-fallopian-tube-and-peritoneum-a-population-based-comparison-of-the-prognostic-factors-and-outcomes
#6
Miriam Rottmann, A Burges, S Mahner, C Anthuber, T Beck, D Grab, A Schnelzer, M Kiechle, D Mayr, M Pölcher, G Schubert-Fritschle, J Engel
PURPOSE: The objective was to compare the prognostic factors and outcomes among primary ovarian cancer (OC), fallopian tube cancer (FC), and peritoneal cancer (PC) patients in a population-based setting. METHODS: We analysed 5399 OC, 327 FC, and 416 PC patients diagnosed between 1998 and 2014 in the catchment area of the Munich Cancer Registry (meanwhile 4.8 million inhabitants). Tumour site differences were examined by comparing prognostic factors, treatments, the time to progression, and survival...
April 26, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28447112/-imaging-diagnostics-of-breast-metastases-from-extramammary-tumors
#7
REVIEW
S Wienbeck, S Nemat, J Lotz, A Surov
Breast metastases of solid extramammary tumors are very rare in comparison to primary malignancies of the breast and account for only 0.33-6.3% of all malignant neoplasms of the breast. The most common primary tumors are malignant melanoma, distant sarcomas, lung cancer, ovarian cancer, renal cell cancer and thyroid cancer in decreasing order of frequency. This review article summarizes the clinical features and the different imaging findings of breast metastases from different extramammary solid tumors. Breast metastases are often incidental findings in computed tomography (CT) or positron emission tomography CT (PET-CT) imaging...
April 26, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28446239/dasatinib%C3%A2-%C3%A2-gefitinib-a-non-platinum-based-combination-with-enhanced-growth-inhibitory-anti-migratory-and-anti-invasive-potency-against-human-ovarian-cancer-cells
#8
Benoît Thibault, Bertrand Jean-Claude
BACKGROUND: Ovarian cancer is the leading cause of death for gynecological cancers and the 6th cause of women cancer death in developed countries. The late stage detection, the peritoneal dissemination and the acquisition of resistance against carboplatin are the main reasons to explain this poor prognosis and strengthen the need of alternative treatments to improve the management of ovarian cancer and/or to sensitize tumors to platinum salts. Epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (Met) and cellular Src kinase (c-Src) are crucial kinases implied in ovarian tumor growth, survival, invasion and resistance to carboplatin...
April 26, 2017: Journal of Ovarian Research
https://www.readbyqxmd.com/read/28445974/lowered-expression-of-microrna-125a-5p-in-human-hepatocellular-carcinoma-and-up-regulation-of-its-oncogenic-targets-sirtuin-7-matrix-metalloproteinase-11-and-c-raf
#9
Nicola Coppola, Giorgio de Stefano, Marta Panella, Lorenzo Onorato, Valentina Iodice, Carmine Minichini, Nicola Mosca, Luisa Desiato, Nunzia Farella, Mario Starace, Giulia Liorre, Nicoletta Potenza, Evangelista Sagnelli, Aniello Russo
Human microRNA-125a-5p (miR-125a) is expressed in most tissues where it downregulates the expression of membrane receptors or intracellular transductors of mitogenic signals, thus limiting cell proliferation. Expression of this miRNA generally increases with cell differentiation whereas it is downregulated in several types of tumors, such as breast, lung, ovarian, gastric, colon, and cervical cancers, neuroblastoma, medulloblastoma, glioblastoma, and retinoblastoma. In this study, we focused on hepatocellular carcinoma and used real-time quantitative PCR to measure miR-125a expression in 55 tumor biopsies and in matched adjacent non-tumor liver tissues...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445301/the-value-of-red-cell-distribution-width-in-patients-with-ovarian-cancer
#10
Yuanyuan Qin, Peng Wang, Zhibi Huang, Gaoming Huang, Jingguang Tang, Yi Guo, Ping Huang, Zhanfeng Lai, Faquan Lin
BACKGROUND: The red cell distribution width (RDW) has attracted attention in the diagnosis of malignant tumors. In this study, we analyzed the correlation between the RDW and ovarian cancer by observing changes in the RDW in patients with ovarian cancer. METHODS: Patients diagnosed with ovarian cancer at the First Affiliated Hospital of Guangxi Medical University, China, from 2012 to 2016, were retrospectively analyzed. Patients diagnosed with ovarian benign tumors in our hospital during the same period comprised the control group...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28445129/tea-consumption-and-the-risk-of-ovarian-cancer-a-meta-analysis-of-epidemiological-studies
#11
Xin Zhan, Jie Wang, Shufen Pan, Caijuan Lu
A large number of epidemiological studies have provided conflicting results about the relationship between tea consumption and ovarian cancer. This study aimed to clarify the association between tea consumption and ovarian cancer. A literature search of the MEDICINE, Scopus, PubMed, and Web of Science databases was performed in April 2016. A total of 18 (11 case-control and 7 cohort) studies, representing data for 701,857 female subjects including 8,683 ovarian cancer cases, were included in the meta-analysis...
April 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28444641/correlation-of-preoperative-roma-scores-with-clinical-stage-in-epithelial-ovarian-cancer-patients
#12
Q-L Li, C-J Wang, P Qi, Y-X Zhang
PURPOSE: The significance of the Risk of Ovarian Malignancy Algorithm (ROMA) in differentiating benign and malignant ovarian lesions has been evidenced. In our clinical work, we found that advanced ovarian cancer were accompanied commonly with high ROMA scores. Thus, this study aimed to clarify the performance of ROMA in different disease stage of epithelial ovarian cancer (EOC) prior to surgery. METHODS: Carbohydrate antigen (CA125) and human epididymis protein 4 (HE4) levels and ROMA scores in 221 patients with FIGO stage I, II or III/IV stage EOC were analyzed...
April 25, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28444622/a-brief-review-of-the-management-of-platinum-resistant-platinum-refractory-ovarian-cancer
#13
REVIEW
Bryan Oronsky, Carolyn M Ray, Alexander I Spira, Jane B Trepel, Corey A Carter, Hope M Cottrill
Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis...
June 2017: Medical Oncology
https://www.readbyqxmd.com/read/28444134/characterization-of-foxo1-3-and-4-transcription-factors-in-ovaries-of-fetal-prepubertal-and-adult-rhesus-macaques
#14
Alison Y Ting, Mary B Zelinski
The phosphoinositide 3-kinase/AKT signaling pathway negatively regulates follicle activation via the forkhead box O (FOXO) transcription factor in rodents. FOXO3 knockout mice exhibit global activation of primordial follicles leading to early depletion of ovarian follicles and subsequent infertility. Whether a similar mechanism for follicle activation exists in the primate ovary is unclear. In the current study, protein localization of FOXO1, 3 and 4 as well as their upstream regulator, AKT/p-AKT, were examined in rhesus macaque ovaries of 3 developmental stages: fetal, prepubertal and adult...
April 22, 2017: Biology of Reproduction
https://www.readbyqxmd.com/read/28444120/premenopausal-hysterectomy-and-risk-of-ovarian-cancer-in-african-american-women
#15
Lauren C Peres, Anthony J Alberg, Elisa V Bandera, Jill Barnholtz-Sloan, Melissa Bondy, Michele L Cote, Ellen Funkhouser, Patricia G Moorman, Edward S Peters, Ann G Schwartz, Paul D Terry, Sarah E Abbott, Fabian Camacho, Frances Wang, Joellen M Schildkraut
Although the inverse association between hysterectomy and epithelial ovarian cancer (EOC) was considered well established, investigators in recent studies including women diagnosed after 2000 have observed modest increases in risk. Most studies have been conducted in white women with little representation of African-American women. We examined the relationship between premenopausal hysterectomy and EOC in African-American women and explored whether hormone therapy (HT) modified this association in 614 cases and 743 controls enrolled in the African American Cancer Epidemiology Study (2010-2015)...
April 21, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/28443762/prediction-of-therapy-response-in-ovarian-cancer-where-are-we-now
#16
Khalid El Bairi, Mariam Amrani, Abdul Hafeez Kandhro, Said Afqir
Therapy resistance is a major challenge in the management of ovarian cancer (OC). Advances in detection and new technology validation have led to the emergence of biomarkers that can predict responses to available therapies. It is important to identify predictive biomarkers to select resistant and sensitive patients in order to reduce important toxicities, to reduce costs and to increase survival. The discovery of predictive and prognostic biomarkers for monitoring therapy is a developing field and provides promising perspectives in the era of personalized medicine...
April 26, 2017: Critical Reviews in Clinical Laboratory Sciences
https://www.readbyqxmd.com/read/28443693/confounder-factors-masking-a-leydig-cell-ovarian-tumor-in-a-post-menopausal-woman-treated-for-androgen-positive-receptor-breast-cancer
#17
Felipe Scipião Moura, Flávia A Costa-Barbosa, Sydney Correia Leao, Sergio Mancini Nicolau, Claudio E Kater, Patrícia T Monteagudo
Post-menopause hyperandrogenism is a condition that needs careful evaluation. Aromatase inhibitors (AI), which are important in the management of positive estrogen breast cancer, and chronic kidney disease (CKD) can puzzle the evaluation of this condition. A postmenopause female with type-2 diabetes and advanced CKD was attended due to progressive virilization, which has started after the introduction of an AI for breast cancer 5 years earlier. Clinical and radiological investigation has confirmed a pure Leydig cell tumor as source of hyperandrogenism...
April 26, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28443516/synergistic-effect-of-graphene-oxide-coated-nanotised-apigenin-with-paclitaxel-go-na-ptx-a-ros-dependent-mitochondrial-mediated-apoptosis-in-ovarian-cancer
#18
Manish Kumar Pal, Shyam Pyari Jaiswar, Ashish Dwivedi, Shruti Goyal, Vinay Nand Dwivedi, Anumesh Kumar Pathak, Vinod Kumar, Pushp Lata Sankhwar, Ratan Singh Ray
Ovarian cancer is most lethal among all gynecologic malignancies. Paclitaxel (PTX) is well used chemotherapeutic regimen for cancer control; however its undesired toxicity has been always a matter of concern for clinicians. Here we used the graphene oxide coated nanotised apigenin (GO-NA) as chemo sensitizing agent to enhance the efficacy of paclitaxel to overcome the limitations of chemotherapy. GO and GO-Apigenin was prepared by modified Hummers method and the nanoparticles were characterized by dynamic light scattering and transmission electron microscopy Human ovarian adenocarcinomas (SKOV-3) cells was treated by DMSO, Group I (Control)-McCoy's 5A Medium, Group II-Paclitaxel (5nM) alone, Group III- Nanotised Apigenin (GO-NA-10μM) Group IV- Paclitaxel (5nM) + GO-NA (10μM)...
April 24, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28443505/targeted-therapy-of-ovarian-cancer-with-angiogenesis-inhibitors
#19
Ping Duan, Lili Fan, Quansheng Gao, Mukunda Silwal, Mulan Ren, Yang Shen, Wanglei Qu
Specific blocking of interactions between ligands and receptors along the angiogenic pathways represent an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis...
March 28, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28443461/mir-1202-functions-as-a-tumor-suppressor-in-glioma-cells-by-targeting-rab1a
#20
Yu Quan, Qian Song, Jvbo Wang, Lingyu Zhao, Jian Lv, Shouping Gong
Aberrant expression of microRNAs correlates with the development and progression of human cancers by targeting downstream proteins. MiR-1202 is downregulated in ovarian cancer and clear cell papillary renal cell carcinoma; however, its role in glioma remains unknown. The purpose of this study was to determine the expression and the role of miR-1202 and to elucidate its regulatory mechanism in glioma. We used quantitative real-time polymerase chain reaction to measure miR-1202 expression in both glioma tissues and cell lines...
April 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
keyword
keyword
98453
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"